Internationally recognized for novel approaches to treating leukemia, lymphoma, and myeloma
Established in 1984, the Duke Adult Blood and Marrow Transplant (ABMT) Program has treated over 3,000 patients from all over the world. The program was expanded in 1996 to include allogeneic patients as well as autologous transplant patients.
Many of those patients return to share their inspirational stories at the annual patient reunion each summer.
Our multidisciplinary team includes highly trained physicians, nurse-practitioners, social workers, pharmacists, nutritionists, physical therapists, clinical researchers, and even financial advisors, all working together to create individualized treatment regimens designed to meet each patient’s unique needs.
In addition to pioneering research in the treatment of breast cancer with autologous bone marrow/stem cell transplantation, Duke’s Blood and Marrow Transplant Program is recognized for its innovative approaches to the treatment of leukemia, lymphoma, and myeloma.
Duke has also received acclaim for its extensive studies of how other cancer treatments can best be combined with transplantation. These include immunotherapy, anti-angiogenesis therapy, and the latest chemotherapy and pharmacologic therapies.
The result of these efforts is a program unsurpassed in the Southeast and unequalled in most parts of the world.
Every year, hundreds of patients receive bone marrow or stem cell transplantation at Duke; nearly half of them come from other states or other countries.